Lexicon Pharma (NASDAQ: LXRX) reported Q4 EPS of ($0.04), $0.24 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $110 thousand.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.